Loading clinical trials...
Loading clinical trials...
The BTP (Breakthrough pain)was defined as "a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain". The BTP is a common clinical features in patients with cancer pain (BTcP: breakthrough cancer pain). The prevalence of BTcP is equal to 56%. Currently, the investigators tend to recognize the idiopathic/spontaneous or accident BTcP in the three sub-types: voluntary, non- voluntary and procedural. The diagnosis of BTCP is not always easy because in the cancer patient is normal to observe changes in the intensity of pain during the day, so it is necessary to differentiate slight fluctuations from the presence of real episodes of BTCP, for which is necessary to use a rescue treatment adjusted. In the study will be proposed the use of a diagnostic algorithm, present in the literature, to perform the diagnosis of BTCP. In the presence of BTCP, is important both a correct controlled background pain with major opioids, which can reduce the number and the intensity of the painful episodes, both implement an adjunctive therapy, called "rescue", to be administered at the time which takes over the painful episode using, in this case, an opioid greater.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
AO Universitaria Policlinico di Modena
Modena, Italia, Italy
A.O. Universitaria Parma
Parma, Italia, Italy
Ospedale Magati
Scandiano, Italia, Italy
Azienda USL - Ospedale di Carpi e Mirandola
Carpi, Italy
A.O.U. Arcispedale S. Anna
Ferrara, Italy
Ospedale di Fiorenzuola D'Arda
Fiorenzuola d'Arda, Italy
Ospedale di Lugo
Lugo, Italy
IRCCS-IRST Forlì
Meldola, Italy
Ospedale di Piacenza
Piacenza, Italy
Arcispedale S. Maria Nuova Azienda Ospedaliera
Reggio Emilia, Italy
Start Date
September 1, 2013
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
April 14, 2016
150
ACTUAL participants
Morphine
DRUG
Fentanyl
DRUG
Methadone
DRUG
Buprenorphine
DRUG
Oxycodone
DRUG
Hydromorphone
DRUG
Tapentadol
DRUG
Lead Sponsor
Mario Negri Institute for Pharmacological Research
NCT05839379
NCT06898450
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions